EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 15 May 2025

Almost 100 new medicine approvals tracked; new data gives clearest picture yet of delays for patients 

Learn more.

EFPIA has published new data from two reports, which provide granular detail about why new medicines are available in some countries but not in others.

The third European Access Hurdles Portal report is part of an industry-led initiative to increase visibility regarding the root causes of unavailability of innovative medicines in Europe.

With 100% participation from EFPIA members and covering 94 medicines approved between January 2021 and June 2024, the data clearly shows that the majority of delays (69%) occur after companies have filed and are awaiting a decision from a Member State.

Bladder Cancer Awareness Month

Each year, over 610,000 people worldwide are diagnosed with bladder cancer, while many more patients and survivors continue to be affected by its impact.

Bladder Cancer Awareness Month highlights the critical importance of early detection and timely diagnosis. This year's WBCPC campaign is a call to action for people and communities to unite, share knowledge, and challenge misconceptions.

Explore the WBCPC campaign and join us in spreading awareness.

Events

IHI Call Days - call 11
23 June 2025 (Virtual event)

The IHI Call Days for IHI call 11 will take place from 23 to 30 June 2025 online and will include sessions on the individual... Read more

EU-X-CT Public Stakeholder Conference: Final recommendations launch
24 June 2025 (Brussels, hybrid event)

Borders should no longer be barriers in clinical trials. Read more

Join our team!

We have 2 job opportunities available:

Associate Director Research & Regulatory
Manager, Legal Affairs – Corporate Sustainability & Policy

To apply, please send your CV and cover letter to [email protected].

You can find more details here.

What we are reading

EFPIA and VE feedback on the EC Strategy to support medical countermeasures against public...
On 15 May 2025 (European Commission)

Discover more on EFPIA & Vaccines Europe's position.

Czechs can’t get no, innovation… patients enduring long delays for new meds
On 14 May 2025 (Euractiv)

The latest 'Patients W.A.I.T. Indicator 2024' report, comparing the availability of new medicines across 36 European... Read more

Parliament’s health committee sets ambitious agenda on rare diseases, women’s health, and cancer...
On 14 May 2025 (Euractiv)

The European Parliament’s Public Health Committee (SANT) has expanded its work programme to advance a more ambitious... Read more

Report on analyzing global immunization expenditure from the Office of Health Economics
On 27 April 2025 (Immunization Economics)

Despite their proven societal and economic benefits, funding for immunization programs remains disproportionately... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:[email protected]

	
		OSZAR »